Zelinska, N.,
Skorodokb, J.,
Malievsky, O.,
Rosenfeldd, Ron G.,
Zadike, Zvi,
Korenf, R.,
Vanderf, Sh.,
Hartf, G.,
Radziukg, K. (2016) -modified human GH (hGH) developed for
once-weekly administration in growth hormone deficient (GHD) adults
Deal, C,
Steelman, J,
Vlachopapadopoulou, E,
Stawerska, R,
Silverman, LA;,
Phillip, M,
Kim, HS,
Ko, CW,
Malievskiy, O,
Cara, JF,
Roland, CL,
Taylor, CT,
Valluri, SR,
Wajnrajch, MP,
Pastrak, A,
Miller, BS (2022) the
efficacy and safety of
once-weekly somatrogon with
once-daily somatropin in prepubertal children with
GHD
Zelinska, N.,
Iotova, V.,
Skorodok, J.,
Malievsky, O.,
Peterkova, V.,
Samsonova, L.,
Rosenfeld, Ron G.,
Zadik, Zvi,
Jaron-Mendelson, Michal,
Koren, Ronit,
Amitzi, Leanne,
Raduk, Dmitri,
Hershkovitz, Oren,
Hart, Gili (2017) –modified human GH (MOD-4023) is developed for
once-a-week
dosing regimen in GH-deficient (GHD) adults
Chatelain, Pierre,
Malievskiy, Oleg,
Radziuk, Klaudziya,
Senatorova, Ganna,
Abdou, Magdy O.,
Vlachopapadopoulou, Elpis,
Skorodok, Yulia,
Peterkova, Valentina,
Leff, Jonathan A.,
Beckert, Michael (2017) the pharmacokinetics, pharmacodynamics, safety, and
efficacy of
weekly TransCon GH to that of daily GH in prepubertal